{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:15:49Z","timestamp":1790349349916,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032317","name":"NewAmsterdam Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ahj.2025.07.012","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T15:20:29Z","timestamp":1752765629000},"page":"325-338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib\/ezetimibe on coronary plaque characteristics"],"prefix":"10.1016","volume":"290","author":[{"given":"Cian P.","family":"McCarthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Blankstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Budoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ditmarsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Navar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheerag","family":"Shirodaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle C.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-1798","authenticated-orcid":false,"suffix":"Jr","given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2025.07.012_bib0001","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.07.012_bib0002","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","article-title":"The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity","volume":"27","author":"Bor\u00e9n","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.ahj.2025.07.012_bib0003","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1161\/01.CIR.0000103664.47406.49","article-title":"Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (>or =12 months) follow-up intravascular ultrasound","volume":"108","author":"von Birgelen","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.07.012_bib0004","article-title":"ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"0","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.07.012_bib0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12872-019-1016-4","article-title":"Progression of coronary atherosclerotic plaque burden and relationship with adverse cardiovascular event in asymptomatic diabetic patients","volume":"19","author":"Yang","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ahj.2025.07.012_bib0006","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamacardio.2023.2731","article-title":"Atherosclerotic coronary plaque regression and risk of adverse cardiovascular events: a systematic review and updated meta-regression analysis","volume":"8","author":"Iatan","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2025.07.012_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1359500","article-title":"Computed tomographic angiography measures of coronary plaque in clinical trials: opportunities and considerations to accelerate drug translation","volume":"11","author":"Howden","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ahj.2025.07.012_bib0008","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2025.07.012_bib0009","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of Evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2025.07.012_bib0010","doi-asserted-by":"crossref","first-page":"7999","DOI":"10.1038\/s41598-021-87528-w","article-title":"The effects of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis","volume":"11","author":"Li","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ahj.2025.07.012_bib0011","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz Gregory","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.07.012_bib0012","doi-asserted-by":"crossref","unstructured":"Sabatine Marc S, Giugliano Robert P, Keech Anthony C, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713-1722. doi:10.1056\/NEJMoa1615664","DOI":"10.1056\/NEJMoa1615664"},{"key":"10.1016\/j.ahj.2025.07.012_bib0013","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.07.012_bib0014","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ahj.2024.06.012","article-title":"Achievement of LDL-C <55 mg\/dL among US adults: findings from the cvMOBIUS2 registry","volume":"279","author":"Navar","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2025.07.012_bib0015","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jacc.2019.08.014","article-title":"Therapeutic inertia in cardiovascular disease prevention","volume":"74","author":"Dixon Dave","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.07.012_bib0016","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/CIRCOUTCOMES.122.009787","article-title":"Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: a retrospective cohort study of 322\u2005153 patients","volume":"16","author":"Navar","year":"2023","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2025.07.012_bib0017","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials","volume":"265","author":"Pandor","year":"2009","journal-title":"J Intern Med"},{"key":"10.1016\/j.ahj.2025.07.012_bib0018","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2025.07.012_bib0019","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.07.012_bib0020","doi-asserted-by":"crossref","DOI":"10.1111\/hex.14043","article-title":"Patient versus physician preferences for lipid-lowering drug therapy: a discrete choice experiment","volume":"27","author":"Zhang","year":"2024","journal-title":"Health Expect"},{"key":"10.1016\/j.ahj.2025.07.012_bib0021","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11883-023-01087-1","article-title":"Structure-based mechanism and inhibition of cholesteryl ester transfer protein","volume":"25","author":"Xue","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ahj.2025.07.012_bib0022","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.07.012_bib0023","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.07.012_bib0024","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.07.012_bib0025","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of Anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.07.012_bib0026","doi-asserted-by":"crossref","first-page":"37321","DOI":"10.1074\/jbc.M112.380063","article-title":"Crystal structures of cholesteryl ester transfer protein in complex with inhibitors","volume":"287","author":"Liu","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ahj.2025.07.012_bib0027","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bcp.12380","article-title":"Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects","volume":"78","author":"Ford","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2025.07.012_bib0028","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11883-025-01276-0","article-title":"Highlights of cardiovascular disease prevention studies presented at the 2024 American Heart Association Scientific sessions","volume":"27","author":"Hermel","year":"2025","journal-title":"Current Atheroscler Rep"},{"key":"10.1016\/j.ahj.2025.07.012_bib0029","doi-asserted-by":"crossref","unstructured":"Nicholls Stephen J, Nelson Adam J, Ditmarsch M, et al. Safety and efficacy of Obicetrapib in patients at high cardiovascular risk. N Engl J Med. 0doi:10.1056\/NEJMoa2415820","DOI":"10.1056\/NEJMoa2415820"},{"key":"10.1016\/j.ahj.2025.07.012_bib0030","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(25)00721-4","article-title":"Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Sarraju","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2025.07.012_bib0031","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.07.012_bib0032","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(11)61383-4","article-title":"Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial","volume":"378","author":"Fayad","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2025.07.012_bib0033","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jcmg.2023.03.007","article-title":"Impact of patient visualization of cardiovascular images on modification of cardiovascular risk factors","volume":"16","author":"Whitmore","year":"2023","journal-title":"JACC Cardiovasc Imag"},{"key":"10.1016\/j.ahj.2025.07.012_bib0034","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.atherosclerosis.2015.06.007","article-title":"Effects of intensive lipid-lowering therapy on coronary plaques composition in patients with acute myocardial infarction: assessment with serial coronary CT angiography","volume":"241","author":"Auscher","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2025.07.012_bib0035","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.2016.21043","article-title":"Testosterone treatment and coronary artery plaque volume in older men with low testosterone","volume":"317","author":"Budoff","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2025.07.012_bib0036","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.07.012_bib0037","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/jamacardio.2023.5661","article-title":"Effects of pitavastatin on coronary artery disease and inflammatory biomarkers in HIV: mechanistic substudy of the REPRIEVE randomized clinical trial","volume":"9","author":"Lu","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2025.07.012_bib0038","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2352-3018(14)00032-0","article-title":"Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Lo","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ahj.2025.07.012_bib0039","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.amjcard.2024.08.002","article-title":"Randomized comparison of progression of atherosclerotic plaques and calcification of coronary artery in atrial fibrillation patients treated with edoxaban versus warfarin (The REPRESENT-AF trial)","volume":"229","author":"Ahn","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2025.07.012_bib0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jcct.2024.01.013","article-title":"No evidence of coronary plaque stabilization by allopurinol in patients with acute coronary syndrome","volume":"18","author":"Yu","year":"2024","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.ahj.2025.07.012_bib0041","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(24)00596-8","article-title":"Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study","volume":"403","author":"Chan","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2025.07.012_bib0042","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jcmg.2022.02.004","article-title":"Pericoronary adipose tissue attenuation, low-attenuation plaque burden, and 5-year risk of myocardial infarction","volume":"15","author":"Tzolos","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2025.07.012_bib0043","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s10557-022-07343-x","article-title":"Implications of ACC\/AHA versus ESC\/EAS LDL-C recommendations for residual risk reduction in ASCVD: a simulation study from DA VINCI","volume":"37","author":"Vallejo-Vaz","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ahj.2025.07.012_bib0044","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ahj.2025.07.012_bib0045","doi-asserted-by":"crossref","unstructured":"Kastelein John JP, van Leuven Sander I, Burgess L, et al. Effect of Torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 356:1620-1630. doi:10.1056\/NEJMoa071359","DOI":"10.1056\/NEJMoa071359"},{"key":"10.1016\/j.ahj.2025.07.012_bib0046","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(07)61088-5","article-title":"Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial","volume":"370","author":"Bots","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2025.07.012_bib0047","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nature Med"},{"key":"10.1016\/j.ahj.2025.07.012_bib0048","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","article-title":"Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial","volume":"17","author":"Ballantyne","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ahj.2025.07.012_bib0049","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/jamacardio.2023.5661","article-title":"Effects of pitavastatin on coronary artery disease and inflammatory biomarkers in HIV: mechanistic substudy of the REPRIEVE randomized clinical trial","volume":"9","author":"Lu","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2025.07.012_bib0050","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon Steven","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.07.012_bib0051","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.07.012_bib0052","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2010.12.006","article-title":"In vivo CT detection of lipid-rich coronary artery atherosclerotic plaques using quantitative histogram analysis: a head to head comparison with IVUS","volume":"215","author":"Marwan","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2025.07.012_bib0053","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jcct.2013.08.006","article-title":"Coronary CT angiography versus intravascular ultrasound for estimation of coronary stenosis and atherosclerotic plaque burden: a meta-analysis","volume":"7","author":"Fischer","year":"2013","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.ahj.2025.07.012_bib0054","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ijcard.2015.01.021","article-title":"In vivo evaluation of fibrous cap thickness by optical coherence tomography for positive remodeling and low-attenuation plaques assessed by computed tomography angiography","volume":"182","author":"Sato","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2025.07.012_bib0055","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.124.017112","article-title":"Intraindividual comparison of ultrahigh-spatial-resolution photon-counting detector CT and energy-integrating detector CT for coronary stenosis measurement","volume":"17","author":"Vecsey-Nagy","year":"2024","journal-title":"Circ Cardiovasc Imag"},{"key":"10.1016\/j.ahj.2025.07.012_bib0056","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1161\/CIRCULATIONAHA.119.044720","article-title":"Low-attenuation noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction","volume":"141","author":"Williams","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.07.012_bib0057","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.jacc.2018.02.079","article-title":"Coronary atherosclerotic precursors of acute coronary syndromes","volume":"71","author":"Chang","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.07.012_bib0058","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jcmg.2023.05.020","article-title":"AI-guided quantitative plaque staging predicts long-term cardiovascular outcomes in patients at risk for atherosclerotic CVD","volume":"17","author":"Nurmohamed","year":"2024","journal-title":"JACC Cardiovasc Imag"},{"key":"10.1016\/j.ahj.2025.07.012_bib0059","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2658","article-title":"Detecting human coronary inflammation by imaging perivascular fat","volume":"9","author":"Antonopoulos","year":"2017","journal-title":"Sci Transl Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325002212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325002212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:06:01Z","timestamp":1778943961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870325002212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":59,"alternative-id":["S0002870325002212"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2025.07.012","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib\/ezetimibe on coronary plaque characteristics","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2025.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}